This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

A Distant Second Choice to Drug-Eluting Stent Placement

Debabrata Mukherjee, MD; David J. Moliterno, MD

JAMA. 2006;295:1307-1309. Published online March 12, 2006 (doi:10.1001/jama.295.11.1307).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The greatest recent mechanical advance in percutaneous coronary revascularization (PCR) has been the development of bare-metal stents, which compared with traditional balloon angioplasty substantially reduce angiographic restenosis and the need for repeat target vessel revascularization (TVR). Stents provide a larger arterial lumen diameter immediately postprocedure (acute gain), although their drawback is an increased reparative response of neointimal formation (late loss). Fortunately, the net gain remains greatest with stents compared with other PCR devices. In less complex lesions, the rate of TVR with bare-metal stents is approximately 10% to 15%, although this rate has been reported to be 2- to 3-fold higher in more complex lesions and unique patient subsets.^1-2 In 2003, at a time when the use of bare-metal stents peaked, approximately 1 million coronary stents were placed in patients hospitalized in the United States.³ Even with a conservative estimate, this means at . . . [Full Text of this Article]

Author Affiliations: The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington.

RELATED ARTICLES

Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The TAXUS V ISR Randomized Trial
Gregg W. Stone, Stephen G. Ellis, Charles D. O’Shaughnessy, Steven L. Martin, Lowell Satler, Thomas McGarry, Mark A. Turco, Dean J. Kereiakes, Lynne Kelley, Jeffrey J. Popma, Mary E. Russell, and for the TAXUS V ISR Investigators
JAMA. 2006;295(11):1253-1263.
ABSTRACT | FULL TEXT  

Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial
David R. Holmes, Jr, Paul Teirstein, Lowell Satler, Michael Sketch, James O’Malley, Jeffery J. Popma, Richard E. Kuntz, Peter J. Fitzgerald, Hong Wang, Eileen Caramanica, Sidney A. Cohen, and for the SISR Investigators
JAMA. 2006;295(11):1264-1273.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Optimal treatment for in-stent restenosis after BMS--DES, coated balloon, or scalpel?
Mukherjee
Eur Heart J 2008;29:1595-1596.
FULL TEXT  

Drug-Eluting Stents vs. Brachytherapy for Bare-Metal In-Stent Restenosis
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT